key: cord-0836582-rmilw4s4
authors: McEllistrem, M. Catherine; Clancy, Cornelius J.; Buehrle, Deanna J.; Lucas, Aaron; Pruskowski, Jennifer; Handler, Steven M.; Decker, Brooke K.
title: Introduction of the BNT162b2 vaccine during a COVID-19 nursing home outbreak
date: 2021-08-05
journal: Am J Infect Control
DOI: 10.1016/j.ajic.2021.07.019
sha: 5a26f390b8e82786e9f22b3dd75e60ef547f1f12
doc_id: 836582
cord_uid: rmilw4s4

BACKGROUND: Coronavirus disease 2019 (COVID-19) outbreaks often occur in nursing homes and prompt frequent surveillance testing for SARS-CoV-2. A single dose of the BNT162b2 vaccine reduces viral load and transmission. In this study, we describe the real-world efficacy of BNT162b2 single-dose vaccination during a COVID-19 outbreak at a Veterans Affairs Community Living Center (CLC). METHODS: From 12/2/20-5/14/21, twice weekly antigen testing was used to detect COVID-19 among 146 residents at the CLC. Residents without a prior history of COVID-19 who agreed to immunization were vaccinated with the BNT162b2 vaccine on 12/16/20 and 1/6/21. Single-dose vaccine efficacy was determined for days 1-21 and days 14-21 after the first vaccine dose. RESULTS: The outbreak occurred from 12/2/20-1/7/21 with an attack rate of 30.8% (45/146); 46.7% (21/45) of the cases were due to asymptomatic COVID-19. One unit accounted for 77.8% (35/45) of the cases. In the vaccine analysis, 116 residents were a median age of 74.5 years and 93.1% (108/116) had ≥ 1 comorbid condition. Between the first and second dose, 15.5% (15/97) of vaccinated residents, and 21.2% (4/19) of unvaccinated residents developed COVID-19 (p=0.81). One week after the second dose, no cases of COVID-19 occurred. CONCLUSIONS: Albeit limited by the small numbers, a single dose of the BNT162b2 vaccine was not efficacious at preventing COVID-19 during this nursing home outbreak.

Of those with Coronavirus disease 2019 in the United States, approximately 50% of the hospitalizations, 50% of the intensive care unit admissions, and 80% of the deaths occurred in adults ≥ 65 years of age, with the highest fatality being among those ≥ 85 years of age 1 . Nursing home residents, in particular, are at high risk of hospitalization and death 2 . Given the high mortality rate, the United States Centers for Disease Control and Prevention (CDC) recommended in December 2020 that nursing home residents and healthcare workers (HCW) be the first to be vaccinated with a mRNA COVID-19 vaccine 3 . The real-world vaccine efficacy 14-20 days after the first dose of the BNT162b2 vaccine against symptomatic COVID-19 in a nationwide vaccination program was 57% (95% CI, 50-63%) overall, 44% (95% CI, 19%-64%) among individuals ≥ 70 years of age, and 62% (CI, 43%-77%) among those with at least three co-morbid conditions 4 . Among those who developed asymptomatic COVID-19 despite a single dose of the BNT162b2 vaccine, a 2.4 mean log 10 lower nasopharyngeal viral load was observed in vaccinated compared to unvaccinated nursing home residents 5 . Moreover, single dose vaccination with either the BNT162b2 vaccine or the ChAdOx1 nCoV-19 vaccine reduced transmission by 40-50% 6 .

Interrupting transmission is a key method of controlling outbreaks, and the CDC recommends surveillance SARS-CoV-2 testing of all nursing home residents and HCW every 3-7 days if a case of COVID-19 is detected 7 . The BD Veritor rapid antigen test has a sensitivity of ~80% for detecting symptomatic disease, especially in those with a high viral load 8 ; however, antigen tests have been shown to have a sensitivity of only ~40% for asymptomatic disease 9 .

Moreover, given relatively low specificity in detecting asymptomatic infections, the CDC recommends that a positive antigen test result in an asymptomatic person without a known COVID-19 exposure be confirmed with a RT-PCR test 10 . COVID-19 nursing home outbreak models suggest that a point-of-care (POC) test with a 50% sensitivity that is completed every three days will prevent 80% of the cases 11 . One real-world outbreak also demonstrated the effectiveness of POC testing every 3-5 days, with an outbreak of 27 residents lasting less than 2 weeks in duration 12 .

While vaccine efficacy trials 13 and active surveillance with POC antigen testing models 11 suggest that each will be instrumental in controlling nursing home COVID-19 outbreaks, the effectiveness of combining these interventions are not well described. A real-world outbreak where the individuals are older and sicker 14 than patients evaluated in the BNT162b2 randomized controlled vaccine trial 13 is a practical method of evaluating efficacy under realworld conditions. One study reported an efficacy of 66% of the BNT162b2 vaccine from 15 days after the first dose through 7 days after the second dose during two 4-to 5-week long nursing home outbreaks with attack rates ranging from 17.8%-28.2%; however, the 95% confidence intervals of efficacy were wide ranging from 29%-83% 15 . In this study, we describe the only COVID-19 outbreak at our Community Living Center (CLC) nursing facility from 12/2/20- 

Residents without a prior history of COVID-19 who agreed to immunization were vaccinated with the BNT162b2 vaccine on 12/16/20. On 1/6/21, three weeks after the first dose, eligible and willing residents received the second dose of the BNT162b2 vaccine. These residents were compared to residents who declined BNT162b2 immunization. Residents who had at least one of the following co-morbid conditions were considered at increased risk of severe COVID-19: active cancer, chronic kidney disease, chronic obstructive pulmonary disease, diabetes, coronary artery disease, congestive heart failure, transplant, and/or body mass index ≥ 30 kg/m 2 .

Symptomatic disease was defined per the BNT162b2 vaccine randomized controlled trial 13 , with COVID-19-related symptoms and/or a temperature ≥ 100.4 °F within 4 days of a nares or nasopharyngeal sample positive for SARS-CoV-2. Symptoms included new or increased cough, new or increased shortness of breath, chills, new or increased muscle pain, new loss of taste or smell, sore throat, diarrhea, or vomiting 13 . Residents in the vaccine analysis were censored if they developed asymptomatic or symptomatic COVID-19 confirmed with an RT-PCR test for SARS-CoV-2 or declined the second dose of the BNT162b2 vaccine. Residents were also censored if they were hospitalized at an acute care hospital on 1/6/21. As well, residents were censored if they either were discharged to home or died between 12/16/20-1/6/21. The hazard ratio of cumulative incidence of asymptomatic and symptomatic cases of COVID-19 from days 1-21 and days 14-21 were calculated using the log-rank test to determine the 95% confidence intervals (CI) and p-values. Table 1 ). The median age, the proportion who were ≥ 65 years of age, the proportion who had at least one comorbid condition, and the proportion who had at least three comorbid conditions associated with severe disease did not differ between vaccinated and unvaccinated residents ( Table 1 ). In contrast, none (0/19) of the unvaccinated compared to 9.3% (9/97) of the vaccinated residents were female (p = 0.001; Table 1 

The residents were assessed at least daily for fever and could voluntarily report a local or systemic reaction. Only 8.2% (8/97) of the residents had a known adverse reaction: 75% (6/8) had a documented fever and 25% (2/8) reported a sore arm.

In this study, a single dose of the BNT162b2 vaccine did not confer protection against COVID-19 during an approximately 5-week-long outbreak at our nursing home. The lack of efficacy of a single dose of the BNT162b2 vaccine detected could have been due to a type II error as only 19 residents remained unvaccinated during the study period. Larger studies have shown that a single dose of the BNT162b2 vaccine has lower efficacy among nursing home residents 15 , and older people with multiple co-morbidities compared to healthier individuals 4 ; thus, the ability to detect a difference, should it be present, might require a larger sample size.

The arrest of the outbreak, with an attack rate of 30.8%, was likely achieved by reducing transmission among residents and among HCW. Given strict visitations restrictions during the study period, the HCW were the main source of community contact for the residents. Among residents, the facility-wide twice weekly surveillance POC testing for SARS-CoV-2 detected cases of COVID-19 early in the disease 11 , nearly 50% of which were asymptomatic. Moreover, the rapid transfer of residents with a positive SARS-CoV-2 test to a separate unit comprised of solely SARS-CoV-2 positive individuals further reduced exposure to uninfected residents. While a single dose of the BNT162b2 vaccine was not efficacious at preventing COVID-19 during this nursing home outbreak, one dose of this vaccine likely reduced transmission 5,6 . Among HCW, nearly 50% received at least one dose of the BNT162b2 vaccine during the study period, which has a real-world efficacy of 80% against COVID-19 in this population 20 . Moreover, some HCW likely had immunity through prior COVID-19 as seroprevalence studies have shown that between 3.7% 21 -11.1% 22 of Pennsylavania residents had immunity by September 2020, three months before this outbreak began. Taken together, HCW immunity to SARS-CoV-2 at the CLC may have reached ~67% during the study period, a level associated with potential herd immunity of SARS-CoV-2 23 .

Although a previous study with similar attack rates touted partial BNT162b2 vaccination as the primary mechanism for controlling a nursing home outbreak, the analysis included cases from day 15 after the first dose through 7 days after the second dose, a timeframe that included full vaccination 15 ; moreover, the reported efficacy was associated with wide confidence intervals 15 . In addition, the previous study also performed active surveillance 1-2 times weekly 15 , and likely immunized their HCW; both of these interventions also likely reduced transmission and curbed the outbreak.

While the lack of efficacy of a single dose of the BNT162b2 vaccine could have been due to a type II error, another explanation was considered. The unvaccinated residents were more likely to be male than the vaccinated residents; however, gender has not been linked to acquisition of COVID-19. In addition to the limitations associated with the vaccine analysis, the HCW immunity data were lacking in two important respects. First, HCW immunization rates from December 2020 -January 2021 were not available. Second, the seroprevalence rates of COVID-19 among HCW in this study were inferred from published data of Pennsylvania residents that was collected 3 month prior to this outbreak 21, 22 . While local reactogenicity to the vaccine was uncommon, the study was not designed or powered to formally evaluate for side effects potentially leading to an undestimation of these events.

Limitations associated with the outbreak focus around SARS-CoV-2 testing. The two asymptomatic residents with a positive POC antigen test should have undergone RT-PCR testing to reduce the risk of false positive results based on the CDC guidelines 10 . The lack of confirmation of negative POC antigen tests, albeit endorsed by the CDC and unfeasible given limited testing resources during the outbreak, could have led to inadvertent transmission thereby potentially lengthening the outbreak duration. Notably, despite continued twice weekly POC antigen screening testing for months after the outbreak, no further positive antigen tests were detected, suggesting a remarkably low rate of false positives.

Notwithstanding these limitations, most notably the small numbers, the data indicate that a single dose of the BNT162b2 vaccine was not efficacious at preventing COVID-19 during this nursing home outbreak.

COVID-19) -United States

Epidemiology of Covid-19 in a Long-Term Care Facility

The Advisory Committee on Immunization Practices' Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine -United States

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Single dose of a mRNA SARS-CoV-2 vaccine is associated with lower nasopharyngeal viral load among nursing home residents with asymptomatic COVID-19

Effect of Vaccination on Household Transmission of SARS-CoV-2 in England

Clinical Evaluation of BD Veritor SARS-CoV-2 Point-of-Care Test Performance Compared to PCR-Based Testing and versus the Sofia 2 SARS Antigen Point-of-Care Test

Performance of an Antigen-Based Test for Asymptomatic and Symptomatic SARS-CoV-2 Testing at Two University Campuses -Wisconsin

Centers for Disease Control and Prevention. Interim Guidance for Antigen Testing for SARS

Modeling effectiveness of testing strategies to prevent COVID-19 in nursing homes -United States

Mitigation of a COVID-19 Outbreak in a Nursing Home Through Serial Testing of Residents and Staff

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

SARS-CoV-2 is associated with high viral loads in asymptomatic and recently symptomatic healthcare workers

Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks -Connecticut

Novel rapid identification of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by real-time RT-PCR using BD Max Open System in Taiwan

Clinical Evaluation of Three Sample-to-Answer Platforms for Detection of SARS-CoV-2

Interim Infection Prevention and Control Recommendations to Prevent SARS-CoV-2 Spread in Nursing Homes

Antibiotic Consumption and Stewardship at a Hospital outside of an Early Coronavirus Disease 2019 Epicenter

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers -Eight U.S. Locations

Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of

Estimated SARS-CoV-2 Seroprevalence in the US as of

Herd Immunity: Understanding COVID-19

Figure 1. Timeline of cases of COVID-19 among vaccinated and unvaccinated residents

All COVID-19 14-21 days after the first dose

Symptomatic COVID-19

Number, b IQR Interquartile Range, c Denominator: Vaccinated = 84 residents, Unvaccinated = 17 residents

No funding was provided for this study. Dr. Clancy has been awarded investigator-initiated research grants from Astellas, Merck, Melinta, and Cidara for studies unrelated to this project, served on advisory boards or consulted for Astellas, Merck, the Medicines Company, Cidara, Scynexis, Shionogi, Qpex and Needham & Company, and spoken at symposia sponsored by Merck and T2Biosystems. The other authors report no conflicts.